Related Experiment Video

Updated: May 7, 2026

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing
06:59

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing

Published on: May 12, 2023

2.0K

[First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer]

Anikó Maráz1, István Bodrogi, András Csejtei

  • 1Onkoterápiás Klinika, Szegedi Tudományegyetem, Szeged, Hungary.

Magyar Onkologia
|October 11, 2013
PubMed

Insights

Pazopanib is an effective first-line treatment for metastatic clear cell renal carcinoma, showing comparable efficacy and good tolerability in Hungarian patients. This study evaluated its safety and effectiveness in managing advanced kidney cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Nephrology

Background:

  • Metastatic clear cell renal carcinoma (mccRCC) is a significant cause of cancer-related mortality.
  • Pazopanib, a tyrosine kinase inhibitor, has emerged as a new therapeutic option for first-line treatment of mccRCC.
  • Evaluating real-world effectiveness and toxicity is crucial for optimizing patient care.

Purpose of the Study:

  • To assess the efficacy and toxicity of first-line pazopanib in patients with metastatic clear cell renal carcinoma.
  • To analyze treatment outcomes based on Memorial Sloan Kettering Cancer Center (MSKCC) prognostic criteria.
  • To provide initial Hungarian clinical experience with pazopanib therapy.

Main Methods:

  • A prospective study involving 21 patients with metastatic clear cell renal carcinoma treated with pazopanib (800 mg daily) across 8 Hungarian oncology centers.
  • Tumor response evaluated using Response Evaluation Criteria In Solid Tumors (RECIST 1.0).
  • Progression-free survival (PFS) and toxicity profiles were monitored, with dose reductions managed per study guidelines.

Main Results:

  • Objective tumor response (CR+PR) observed in 38% of patients (2 Complete Remissions, 6 Partial Remissions).
  • Median progression-free survival (PFS) was 12.41 months.
  • Common adverse events included fatigue (52.4%), weakness (42.9%), and diarrhea (38%); dose reductions occurred in 28.6% of cases.

Conclusions:

  • Pazopanib demonstrates good tolerability and can be safely administered as a first-line treatment for metastatic clear cell renal carcinoma in the Hungarian population.
  • The observed efficacy in terms of tumor response and PFS is comparable to findings from the pivotal registration study.
  • Pazopanib represents a valuable therapeutic option for patients with good and medium prognosis according to MSKCC criteria.

More Related Videos

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

11.4K
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

6.9K

Related Concept Videos

Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
956
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K